The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

The Food and Drug Administration (FDA) has granted traditional approval to Calquence (acalabrutinib) with bendamustine and Rituxan (rituximab) for adults with previously untreated mantle cell lymphoma ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen ...

6% had high-grade B-cell lymphoma (double hit or triple hit), 14% had mantle cell lymphoma, 14% had Richter transformation, and 8% had other indolent lymphoma. The median number of previous ...

A phase 1 clinical trial has found one such immunotherapy to be safe for patients with several types of B-cell lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.